Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.55 |
| ▸ | GAA | P10253 | 5/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.42 |
| ▸ | UBA2 | Q9UBT2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16740892 | 0.98 | ALDH1A1 (0.96) | ALDH1A1LMNACYP1A2KDM4EGAA | |
| SCHEMBL16747724 | 0.78 | LMNA (0.72) | ALDH1A1LMNACYP1A2KDM4ECYP2C19 | |
| SCHEMBL24757550 | 0.75 | ALDH1A1 (0.60) | ALDH1A1LMNACYP1A2KDM4EGAA | |
| SCHEMBL11577886 | 0.75 | ALDH1A1 (0.60) | ALDH1A1CYP1A2KDM4EGAACYP2C19 | |
| SCHEMBL26361875 | 0.75 | ALDH1A1 (0.59) | ALDH1A1LMNACYP1A2KDM4EGAA | |
| SCHEMBL26287906 | 0.72 | CYP1A2 (1.00) | ALDH1A1LMNACYP1A2KDM4ECYP2C19 | |
| SCHEMBL16740907 | 0.72 | LMNA (0.64) | ALDH1A1LMNAKDM4EGAAHPGD | |
| SCHEMBL29488099 | 0.71 | KDM4E (1.00) | ALDH1A1LMNACYP1A2KDM4EGAA | |
| SCHEMBL824574 | 0.71 | KDM4E (1.00) | ALDH1A1LMNACYP1A2KDM4EGAA | |
| SCHEMBL24995863 | 0.71 | ALDH1A1 (0.55) | ALDH1A1LMNACYP1A2KDM4ECYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111850631-B | High-gloss decorative rhodium-plated layer electroplating solution | 金川集团股份有限公司 | 2021-10-08 | — | — | CN | claimed |
| CN-111850631-A | High-gloss decorative rhodium-plated layer electroplating solution | 金川集团股份有限公司 | 2020-10-30 | — | — | CN | claimed |
| WO-2024108155-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023173017-A1 | KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023173014-A1 | KRAS INHIBITORS AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023173016-A1 | KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023018699-A1 | SELECTIVE KRAS INHIBITORS | ERASCA, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023011533-A1 | COMPOSITIONS AND METHODS OF COMBINATION THERAPY FOR TARGETING LYMPHOMA | CULLGEN (SHANGHAI) , INC. (CN) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022266206-A1 | KRAS INHIBITOR CONJUGATES | ERASCA, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| CN-111850631-B | High-gloss decorative rhodium-plated layer electroplating solution | 金川集团股份有限公司 | 2021-10-08 | — | — | CN | disclosed |
| CN-111850631-A | High-gloss decorative rhodium-plated layer electroplating solution | 金川集团股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-9738630-B2 | Inhibitors of lysine methyl transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738630-B2 | Inhibitors of lysine methyl transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160297806-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297806-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2016-10-13 | — | — | US | disclosed |
| WO-2015077193-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297806-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | EZH2, DOT1L, EHMT1 | ALDH1A1 2301/4885LMNA 3571/4885CYP1A2 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.